DDK 2-4 milion for a period of 1-3 years - August 25, 2026 (Application; Call opens on June 29)
LEO FOUNDATION
The aim is to improve the understanding of the underlying medicimal,biological,chemical or pharmacological mechanisms of dermatological diseases and their symptoms, like skin disease including how it impacts their quality of life and the social costs.
Up to $80,000 or up to $150,000/year, per year + $50,000 may be available via supplemental funding. - Thursday, April 02, 2026 (Letter of Intent); Sunday, August 16, 2026 (Application)
Cystic Fibrosis Foundation (CFF), US
Clinical Pilot and Feasibility Awards are offered to support projects involving human subjects that will develop and test new hypotheses and/or new methods.
Up to $100,000 per year - Saturday, August 15, 2026
Angelman Syndrome Foundation, Inc. (ASF)
The Foundation is committed to funding groundbreaking scientific research that brings us closer to effective treatments and improved care for individuals with Angelman syndrome (AS).
Tier I: Up to $100,000 over 1–2 years; Tier II (PI-initiated): Up to $50,000 over 1–2 years; Tier III: Up to $25,000 over 1 year; Fellow-initiated: $50,000 for 1 year. - August 7, 2026 (LOI)
NATIONAL MPS SOCIETY
This supports innovative research on mucopolysaccharidosis (MPS) and mucolipidosis (ML), spanning basic, translational, and clinical science.
Up to £250,000 excluding the applicant’s salary. - Thursday, November 20, 2025
Wellcome Trust
This scheme provides funding for mid-career researchers from any discipline who have the potential to be international research leaders. They will develop their research capabilities, drive innovative programmes of work and deliver significant shifts in understanding related to human life, health and wellbeing.
$300,000 based on stage and scope of research; One year with potential for follow-on funding - May 11, 2026 (LOI); July 20, 2026 (invited full proposal)
Alzheimer’s Drug Discovery Foundation (ADDF) and Association for Frontotemporal Degeneration (AFTD
The award is open to any new discovery of Alzhaimer's drug.
$55,000. Overhead not allowed. - Preliminary Proposals are accepted annually from June 1 to July 15
Glaucoma Research Foundation
The Foundation aims to fund projects that support new high-impact clinical, epidemiological, and laboratory research based on its strategic research goals.
Indirect costs are no more than 7% of direct costs. In 2020-2025 the median grant was $420,000. Grants are generally not given over $600,000 - Tuesday, July 14, 2026 (Concept note)
Thrasher Research Fund-Medical research grants to improve the lives of children
E.W. "Al" Thrasher Awards focus on projects that are changing pediatric clinical care. Each award is a novel approach to problems plaguing pediatrics.
The aim is to promote evidence-based practices based on research in the following areas:-The analysis, evaluation, or comparison of current models of assessment, intervention, or systems of service delivery, including policy analysis
International Team for Implantology (ITI)
LEO FOUNDATION
Cystic Fibrosis Foundation (CFF), US
Angelman Syndrome Foundation, Inc. (ASF)
NATIONAL MPS SOCIETY
Wellcome Trust
Alzheimer’s Drug Discovery Foundation (ADDF) and Association for Frontotemporal Degeneration (AFTD
Glaucoma Research Foundation
Thrasher Research Fund-Medical research grants to improve the lives of children
PTEN Research, GB
